UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

Prostate cancer kills more than 12,000 men a year in the UK, slightly more than the number of women who die from breast ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

Add Yahoo as a preferred source to see more of our stories on Google. Men whose prostate cancer returns after surgery or radiation therapy may finally have a new treatment that helps them live longer.